

DESCRIPTION

Source	Chinese Hamster Ovary cell line, CHO-derived human CTLA-4 protein		
	Human CTLA-4 (Ala37-Phe162) Accession # P16410	IEGRMD	Human IgG ₁ (Pro100-Lys330)
	N-terminus		C-terminus
N-terminal Sequence Analysis	Ala37 & Met38		
Structure / Form	Disulfide-linked homodimer		
Predicted Molecular Mass	40.1 kDa (monomer)		


SPECIFICATIONS

SDS-PAGE	53-58 kDa, reducing conditions
Activity	Measured by its ability to inhibit IL-2 secretion by stimulated Jurkat human acute T cell leukemia cells. Linsley, P.S. <i>et al.</i> (1991) J. Exp. Med. 174:561. The ED ₅₀ for this effect is 0.03-0.15 µg/mL when stimulated with 1 µg/mL Recombinant Human B7-1/CD80 Fc Chimera (Catalog # 10133-B1).
Endotoxin Level	<0.01 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 100 µg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA



BACKGROUND

CTLA-4 (cytotoxic T-lymphocyte associated protein-4, designated CD152), is a type I transmembrane T cell inhibitory molecule that is a member of the Ig superfamily (1, 2). Human or mouse CTLA-4 cDNA encodes 223 amino acids (aa) including a 35 aa signal sequence, a 126 aa extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane (TM) sequence, and a 41 aa cytoplasmic sequence. It is found as a covalent homodimer of 41-43 kDa (2). Within the ECD, human CTLA-4 shares 68%, 71% and 83-86% aa sequence identity with mouse, rat and porcine/bovine/rabbit/feline/canine CTLA-4, respectively. A 174 aa form that lacks TM and cytoplasmic sequences (sCTLA-4) is possibly secreted (3-5). Isoforms of 56-79 aa that mainly contain parts of the cytoplasmic domain are reported. In mouse, an isoform lacking the Ig-like domain has ligand-independent inhibitory activity and is termed liCTLA-4 (6). CD28, which is structurally related to CTLA-4, is constitutively expressed on naïve T cells and promotes T cell activation when engaged by B7-2 on antigen-presenting cells (APC) within the immunological synapse (IS) (1, 7, 8). In contrast, CTLA-4 is recruited from intracellular vesicles to the IS beginning 1-2 days after T cell activation (2, 7, 8). It forms a linear lattice with B7-1 on APC, inducing negative regulatory signals and ending T cell activation (9). Abatacept, a therapeutic human CTLA-4-Ig fusion protein (trade name Orencia), competes with CD28 for B7-1 and B7-2 binding and has been used to antagonize T cell activation in autoimmune conditions and to enhance transplant survival (10). Mice deleted for CTLA-4 show no abnormalities until after birth, but then develop lethal autoimmune reactions due to continued T cell activation and poor control by regulatory T cells, which constitutively express CTLA-4 in wild-type mice and humans (11-13).

References:

1. Harper, K. *et al.* (1991) *J. Immunol.* **147**:1037.
2. Teft, W.A. *et al.* (2006) *Annu. Rev. Immunol.* **24**:65.
3. Magistrelli, G. *et al.* (1999) *Eur. J. Immunol.* **29**:3596.
4. Tector, M. *et al.* (2009) *BMC Immunol.* **10**:51.
5. Oaks, M.K. and K.M. Hallett (2000) *J. Immunol.* **164**:5015.
6. Vijayakrishnan, L. *et al.* (2004) *Immunity* **20**:563.
7. Pentcheva-Hoang, T. *et al.* (2004) *Immunity* **21**:401.
8. Jansson, A. *et al.* (2005) *J. Immunol* **175**:1575.
9. Darlington, P.J. *et al.* (2005) *J. Immunol.* **175**:996.
10. Platt, A.M. *et al.* (2010) *J. Immunol.* **185**:1558.
11. Wing, K. *et al.* (2008) *Science* **322**:271.
12. Friedline, R.H. *et al.* (2009) *J. Exp. Med.* **206**:421.
13. Jain, N. *et al.* (2010) *Proc. Natl. Acad. Sci. USA* **107**:1524.